Table 1 Clinical and cost estimates in the cost-effectiveness model
Historical quarterly survival and loss to follow-up in the Zambian national ART program from May 2004 through October 2010 stratified by BMI* | |||||
|---|---|---|---|---|---|
BMI (kg/m 2) | Quarter | Patients alive/active at start of quarter | Disposition at end of quarter (%/cumulative %) | ||
| Â | Â | Â | Alive/active | Dead | Loss to follow-up |
<16.0 | Q1; 0-90 days | 5096 | 3649 (71.6 / na) | 881 (17.3 / na) | 566 (11.1 / na) |
| Â | Q2; 91-180 days | 3649 | 3131 (85.8 / 61.4) | 181 (5.0 / 20.8) | 337 (9.2 / 17.7) |
| Â | Q3; 181-270 days | 3131 | 2875 (91.8 / 56.4) | 73 (2.3 / 22.3) | 183 (5.8 / 21.3) |
| Â | Q4; 271-360 days | 2875 | 2689 (93.5 / 52.8) | 40 (1.4 / 23.1) | 146 (5.1 / 24.2) |
16.00 - 16.99 | Q1 | 4439 | 3608 (81.3 / na) | 468 (10.5 / na) | 363 (8.2 / na) |
| Â | Q2 | 3608 | 3222 (89.3 / 72.6) | 124 (3.4 / 13.3) | 262 (7.3 / 14.1) |
| Â | Q3 | 3222 | 2995 (93.0 / 67.5) | 45 (1.4 / 14.4) | 182 (5.7 / 18.2) |
| Â | Q4 | 2995 | 2813 (93.9 / 63.4) | 34 (1.1 / 15.1) | 148 (4.9 / 21.5) |
17.00 - 18.49 | Q1 | 9712 | 8421 (86.7 / na) | 631 (6.5 / na) | 660 (6.8 / na) |
| Â | Q2 | 8421 | 7630 (90.6 / 78.6) | 228 (2.7 / 8.8) | 563 (6.7 / 12.6) |
| Â | Q3 | 7630 | 7177 (94.1 / 73.9) | 103 (1.4 / 9.9) | 350 (4.6 / 16.2) |
| Â | Q4 | 7177 | 6849 (95.4 / 70.5) | 58 (0.8 / 10.5) | 270 (3.8 / 19.0) |
>18.5 | Q1 | 39133 | 35716 (91.3 / na) | 1229 (3.1 / na) | 2188 (5.6 / na) |
| Â | Q2 | 35716 | 33417 (93.6 / 85.4) | 460 (1.3 / 4.3) | 1839 (5.1 / 10.3) |
| Â | Q3 | 33417 | 31850 (95.3 / 81.4) | 251 (0.8 / 5.0) | 1316 (3.9 / 13.7) |
| Â | Q4 | 31850 | 30432 (95.5 / 77.8) | 200 (0.6 / 5.5) | 1218 (3.8 / 16.8) |
Cost estimates (all BMI strata) | |||||
ART treatment | $556 per year ($139 per quarter) | ||||
Health outcomes estimate (all BMI strata) | |||||
Health benefits per AIDS death averted | 7.3 Disability-adjusted life years | ||||